2-Acetoxy-3-methyl-pentanoic acid ethyl ester | 91717-68-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Acetoxy-3-methyl-pentanoic acid ethyl ester
• 英文别名: Ethyl 2-acetyloxy-3-methylpentanoate
• CAS: 91717-68-9
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.251
• InChiKey: IKAAHSAFDVXBPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Process for synthesizing oxidized lactam compounds
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10011569B2

  公开（公告）日：2018-07-03

  The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I:

  本发明提供了一种合成式 I 的脱氢内酰胺药物的方法：
• Heterocyclic compounds for the treatment of neurological and psychological disorders
  申请人：Alkermes Pharma Ireland Limited

  公开号：US11518745B2

  公开（公告）日：2022-12-06

  Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

  公开了式 I 的内酰胺化合物及其在治疗神经和精神疾病（包括精神分裂症、躁郁症、焦虑症和失眠症）方面的用途。
• Process for Synthesizing Oxidized Lactam Compounds
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20170267639A1

  公开（公告）日：2017-09-21

  The invention provides a method for the synthesis of dehydrogenated lactam drugs of Formula I:
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20200407320A1

  公开（公告）日：2020-12-31

  Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.